SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2005
IntraBiotics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-29993
|
|
94-3200380 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
1009 Oak Hill Road, Suite 201
Lafayette, CA 94549
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (925) 906-5331
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| |
|
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| |
|
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| |
|
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
| |
|
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 1.01. Entry into a Material Definitive Agreement.
On October 31, 2005, IntraBiotics Pharmaceuticals, Inc. (“the Company”) amended its agreement
with Hickey & Hill, dated June 20, 2005 (the “Agreement”) to provide for an increase in the monthly
fee payable to Hickey & Hill from $9,000 per month to $12,000 per month, effective September 2005.
In addition, the Company paid a bonus to Hickey & Hill in the
amount of $10,000 for services performed in July and August 2005.
Under the Agreement, Hickey & Hill manages the Company’s
day to day operations. In addition, Denis Hickey, a founding principal of Hickey & Hill, serves as the Chief
Executive Officer and Chief Financial Officer of the Company. The fees payable to Hickey & Hill
include Mr. Hickey’s compensation for service as the
Company’s Chief Executive Officer and Chief Financial Officer.
Item 2.02. Results of Operations and Financial Condition.
On October 27, 2005, IntraBiotics Pharmaceuticals, Inc. (“the Company”) reported its results
of operations for its fiscal quarter ended September 30, 2005. A copy of the press release is
furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Item shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by
reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibit. The following document is filed as an exhibit to this report:
99.1 Press Release dated October 27, 2005.